Ontology highlight
ABSTRACT:
SUBMITTER: Baselga J
PROVIDER: S-EPMC5699974 | biostudies-literature | 2017 Dec
REPOSITORIES: biostudies-literature
Baselga José J Zamagni Claudio C Gómez Patricia P Bermejo Begoña B Nagai Shigenori E SE Melichar Bohuslav B Chan Arlene A Mángel Lászlo L Bergh Jonas J Costa Frederico F Gómez Henry L HL Gradishar William J WJ Hudis Clifford A CA Rapoport Bernardo L BL Roché Henri H Maeda Patricia P Huang Liping L Meinhardt Gerold G Zhang Joshua J Schwartzberg Lee S LS
Clinical breast cancer 20170522 8
<h4>Introduction</h4>Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. In this randomized, double-blind, placebo-controlled phase III trial, we assessed first- or second-line capecitabine with sorafenib or placebo in patients with locally advanced/metastatic HER2-negative breast cancer resistant to a taxane and anthracycline and with known estrogen/progesterone receptor status.<h4>Patients and methods</h4>A total of 537 patients were randomized to capecitabine ...[more]